

CITATION REPORT

List of articles citing

Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjogren's Syndrome

DOI: 10.1002/art.40093

Arthritis and Rheumatology, 2017, 69, 1440-1450.

Source: <https://exaly.com/paper-pdf/66072376/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
162	The value of rituximab treatment in primary Sjögren's syndrome. 2017 , 182, 62-71		29
161	Editorial: Rituximab in the Treatment of Sjögren's Syndrome: Is It the Right or Wrong Drug?. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1346-1349	9.5	13
160	Cutaneous and Mucosal Manifestations of Sjögren's Syndrome. 2017 , 53, 357-370		26
159	Chronic Autoimmune Epithelitis in Sjögren's Syndrome and Primary Biliary Cholangitis: A Comprehensive Review. 2017 , 4, 263-279		17
158	Oral dryness and Sjögren's: an update. 2017 , 223, 649-654		6
157	B Cells Are Indispensable for a Novel Mouse Model of Primary Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 2017 , 8, 1384	8.4	8
156	Biologic Therapy in the Treatment of Sjögren's Syndrome: a Clinical Perspective. 2018 , 4, 85-98		2
155	Primary Sjögren's Syndrome. 2018 , 378, 931-939		268
154	Clinical Efficacy and Safety of Baminercept, a Lymphotoxin α Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1470-1480	9.5	35
153	Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials. <i>Arthritis and Rheumatology</i> , 2018 , 70, 763-773	9.5	31
152	Management of primary Sjögren's syndrome: recent developments and new classification criteria. 2018 , 10, 39-54		17
151	Sjögren's syndrome. 2018 , 46, 126-130		1
150	Mixed-Methods Study Identifying Key Intervention Targets to Improve Participation in Daily Living Activities in Primary Sjögren's Syndrome Patients. 2018 , 70, 1064-1073		8
149	B cells in the pathogenesis of primary Sjögren syndrome. <i>Nature Reviews Rheumatology</i> , 2018 , 14, 133-145.1	15.1	121
148	Effect of rituximab on a salivary gland ultrasound score in primary Sjögren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 412-416	2.4	53
147	Current views on the pathogenesis of Sjögren's syndrome. 2018 , 30, 215-221		23
146	The long and the short of it: insights into the cellular source of autoantibodies as revealed by B cell depletion therapy. 2018 , 55, 81-88		20

145	Interferon activation in primary Sjögren's syndrome: recent insights and future perspective as novel treatment target. 2018 , 14, 817-829		17
144	Advances in the diagnosis and treatment of Sjogren's syndrome. <i>Clinical Rheumatology</i> , 2018 , 37, 1743-1749		21
143	Serum immunoglobulin free light chains are sensitive biomarkers for monitoring disease activity and treatment response in primary Sjögren's syndrome. <i>Rheumatology</i> , 2018 , 57, 1812-1821	3.9	16
142	Translational Research in Sjögren's Syndrome. 2018 , 123-141		
141	Update on Sjögren Syndrome and Other Causes of Sicca in Older Adults. 2018 , 44, 419-436		23
140	Modulation of Apoptosis by Cytotoxic Mediators and Cell-Survival Molecules in Sjögren's Syndrome. 2018 , 19,		12
139	An update on the role of type I interferons in systemic lupus erythematosus and Sjögren's syndrome. 2018 , 30, 471-481		40
138	Tissue-Resident Memory CD8+ T Cells Acting as Mediators of Salivary Gland Damage in a Murine Model of Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2019 , 71, 121-132	9.5	19
137	Rituximab Is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A Phase 2 Randomized Controlled Trial. 2019 , 70, 1646-1657		29
136	[Thirteen reasons why B cell may not be the best therapeutic target in systemic lupus erythematosus]. 2019 , 40, 207-210		0
135	Interventions for dry mouth and hyposalivation in Sjögren's syndrome: A systematic review and meta-analysis. 2019 , 25, 1027-1047		22
134	Emerging drugs for primary Sjögren's syndrome. 2019 , 24, 121-132		7
133	Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome. <i>RMD Open</i> , 2019 , 5, e001064	5.9	24
132	Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. <i>Lancet Rheumatology, The</i> , 2019 , 1, e85-e94	14.2	38
131	Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders. <i>Frontiers in Immunology</i> , 2019 , 10, 1990	8.4	58
130	Managing fatigue in patients with primary Sjögren's syndrome: challenges and solutions. 2019 , 11, 77-88		12
129	Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1812-1823	9.5	40
128	Disease activity and patient reported outcome measures in Sjögren's - what are the best tools to evaluate?. <i>Rheumatology</i> , 2019 ,	3.9	4

127	World Workshop on Oral Medicine VII: Immunobiologics for salivary gland disease in Sjögren's syndrome: A systematic review. 2019 , 25 Suppl 1, 102-110		6
126	[Sjögren's syndrome update: Clinical and therapeutic aspects]. 2019 , 40, 433-439		6
125	Salivary gland ultrasonography in primary Sjögren's syndrome: opportunities and challenges. <i>Rheumatology</i> , 2019 ,	3.9	11
124	Treatment of primary Sjögren's syndrome with ialalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 641-647	2.4	69
123	The pipeline of targeted therapies under clinical development for primary Sjögren's syndrome: A systematic review of trials. <i>Autoimmunity Reviews</i> , 2019 , 18, 576-582	13.6	20
122	Salivary Gland Disorders and Diseases. 2019 , 1437-1521		1
121	Innate immunity and interferons in the pathogenesis of Sjögren's syndrome. <i>Rheumatology</i> , 2019 ,	3.9	26
120	B cells in Sjögren's syndrome: from pathophysiology to therapeutic target. <i>Rheumatology</i> , 2019 ,	3.9	14
119	Health-related quality of life and costs in Sjögren's syndrome. <i>Rheumatology</i> , 2019 ,	3.9	13
118	SER recommendations on the use of biological drugs in primary Sjögren's syndrome. 2019 , 15, 315-326		5
117	Gene Expression Profiles in Primary Sjögren's Syndrome With and Without Systemic Manifestations. <i>ACR Open Rheumatology</i> , 2019 , 1, 603-613	3.5	5
116	SER recommendations on the use of biological drugs in primary Sjögren's syndrome. 2019 , 15, 315-326		
115	Disease activity and damage in patients with primary Sjögren's syndrome: Prognostic value of salivary gland ultrasonography. 2019 , 14, e0226498		16
114	Can We Expect Any Effect of Rituximab on Fatigue in Primary Sjögren Syndrome?: A Systematic Review and Critical Appraisal. 2021 , 27, e510-e515		
113	Effects of Xerostom products on xerostomia in primary Sjögren's syndrome: A randomized clinical trial. 2019 , 25, 772-780		1
112	Targeting primary Sjögren's syndrome. <i>Modern Rheumatology</i> , 2019 , 29, 70-86	3.3	11
111	Rituximab in systemic autoimmune rheumatic diseases: indications and practical use. 2019 , 74, 272-279		14
110	Can ultrasound of the major salivary glands assess histopathological changes induced by treatment with rituximab in primary Sjögren's syndrome?. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e27	2.4	4

109	Sleep apnea in Sjögren's syndrome potentially influences the EULAR Sjögren's syndrome patient reported index. <i>Modern Rheumatology</i> , 2019 , 29, 563-565	3.3	1
108	Meta-Analysis of Treatment for Primary Sjögren's Syndrome. 2020 , 72, 1011-1021		9
107	Systems medicine and salivary gland diseases. 2020 , 311-336		
106	EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 3-18	2.4	139
105	Challenges in Treatment of Primary Sjögren's Syndrome and Opportunities for Chinese Medicine. 2020 , 26, 483-485		0
104	Sjögren's syndrome: Old and new therapeutic targets. 2020 , 110, 102364		43
103	Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis. 2020 , 32, 609-616		5
102	Comparison of Rituximab Originator With CT-P10 Biosimilar in Patients With Primary Sjögren's Syndrome: A Retrospective Analysis in a Real-Life Setting. 2020 , 7, 534		4
101	Outcome Measures in Primary Sjögren's Syndrome. 2020 , 72 Suppl 10, 134-149		2
100	Innate Immunity and Biological Therapies for the Treatment of Sjögren's Syndrome. 2020 , 21,		11
99	Current State of Knowledge on Primary Sjögren's Syndrome, an Autoimmune Exocrinopathy. 2020 , 9,		28
98	Association of Primary Sjögren's Syndrome and Vitamin B12 Deficiency: A Cross-Sectional Case-Control Study. 2020 , 9,		1
97	Normal-Appearing Salivary Gland Ultrasonography Identifies a Milder Phenotype of Primary Sjögren's Syndrome. 2020 , 7, 602354		7
96	Adult Measures of General Health and Health-Related Quality of Life. 2020 , 72 Suppl 10, 522-564		7
95	Unstimulated whole saliva flow for diagnosis of primary Sjögren's syndrome: time to revisit the threshold?. 2020 , 22, 38		6
94	Targeted therapies in systemic sclerosis, myositis, antiphospholipid syndrome, and Sjögren's syndrome. 2020 , 34, 101485		7
93	Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study. <i>Lancet Rheumatology, The</i> , 2020 , 2, e142-e152	14.2	34
92	Toward better outcomes in Sjögren's syndrome: The promise of a stratified medicine approach. 2020 , 34, 101475		8

91	Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. <i>2020</i> , 31, 724-744		64
90	Treatment of Sjögren's syndrome: current therapy and future directions. <i>Rheumatology</i> , 2021 , 60, 2066-2074		16
89	Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	22
88	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus. <i>Autoimmunity Reviews</i> , 2021 , 20, 102738	13.6	14
87	Targeted therapies in interstitial lung disease secondary to systemic autoimmune rheumatic disease. Current status and future development. <i>Autoimmunity Reviews</i> , 2021 , 20, 102742	13.6	6
86	A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome. <i>Rheumatology</i> , 2021 , 60, 1364-1375	3.9	10
85	Stimulated whole salivary flow rate: The most appropriate technique for assessing salivary flow in Sjögren syndrome. 2021 , 26, e404-e407		1
84	Pharmacological Management of Sjögren's Syndrome. 2021 , 197-215		0
83	Immune Monitoring upon Treatment with Biologics in Sjögren's Syndrome: The What, Where, When, and How. 2021 , 11,		1
82	New developments in Sjogren's syndrome.. <i>Rheumatology</i> , 2021 , 60, vi53-vi61	3.9	1
81	SS-A52 antigen expression in thymic carcinoma accompanied with Sjögren syndrome: A case report. 2021 , 100, e24491		
80	Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's Syndrome. 2021 , 38, 265-284		0
79	Autoantibodies Targeting Intracellular and Extracellular Proteins in Autoimmunity. <i>Frontiers in Immunology</i> , 2021 , 12, 548469	8.4	10
78	Mortality in patients with primary Sjögren's syndrome: a systematic review and meta-analysis. <i>Rheumatology</i> , 2021 , 60, 4029-4038	3.9	3
77	Epithelial-immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis. <i>Nature Reviews Rheumatology</i> , 2021 , 17, 333-348	8.1	14
76	On- and off-label use of rituximab in rheumatic diseases. 2021 , 3,		
75	References. 2021 , 503-522		
74	Correlation Between Subjective and Objective Severity of Oral and Ocular Dryness in Primary Sjögren Syndrome. 2021 , 48, 1290-1294		1

73	B Cell Activation and Escape of Tolerance Checkpoints: Recent Insights from Studying Autoreactive B Cells. 2021 , 10,		3
72	Instruments for Outcome Evaluation of Specific Domains in Primary Sjögren's Syndrome. 2021 , 11,		0
71	A new molecular classification to drive precision treatment strategies in primary Sjögren's syndrome. 2021 , 12, 3523		15
70	The Multiple Roles of B Cells in the Pathogenesis of Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 2021 , 12, 684999	8.4	2
69	Management of Sjögren's Syndrome: Present Issues and Future Perspectives. 2021 , 8, 676885		3
68	Primary Sjögren's Syndrome: A Retrospective Cohort Study of Burden of Illness in Sweden. 2021 , 8, 955-971		0
67	Current and future therapies for primary Sjögren syndrome. <i>Nature Reviews Rheumatology</i> , 2021 , 17, 475-486	8.1	10
66	Neuro-Sjögren. 2021 , 4, 401-411		
65	Biological Therapy in Primary Sjögren's Syndrome: Effect on Salivary Gland Function and Inflammation. 2021 , 8, 707104		2
64	Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure. <i>Lancet Rheumatology, The</i> , 2021 , 3, e553-e562	14.2	6
63	CRESS: improving the assessment of disease activity in Sjögren's syndrome. <i>Lancet Rheumatology, The</i> , 2021 , 3, e534-e535	14.2	
62	Comparative analysis of the efficacy and safety of herbal decoction CheReCunJin alone and combined with hydroxychloroquine for treating primary Sjögren's syndrome: A randomized controlled trial. <i>Explore: the Journal of Science and Healing</i> , 2021 ,	1.4	1
61	Traitements présents et futurs du syndrome sec au cours du syndrome de Gougerot-Sjögren primitif. <i>Revue Du Rhumatisme Monographies</i> , 2021 , 88, 279-286	0	
60	NKp30 Receptor Upregulation in Salivary Glands of Sjögren's Syndrome Characterizes Ectopic Lymphoid Structures and Is Restricted by Rituximab Treatment. <i>Frontiers in Immunology</i> , 2021 , 12, 706737	8.4	2
59	Rituximab Therapy for Primary Sjögren's Syndrome. <i>Frontiers in Pharmacology</i> , 2021 , 12, 731122	5.6	0
58	Longitudinal analysis of symptom-based clustering in patients with primary Sjögren's syndrome: a prospective cohort study with a 5-year follow-up period. <i>Journal of Translational Medicine</i> , 2021 , 19, 394	8.5	1
57	Autoimmunity in dry eye disease - An updated review of evidence on effector and memory Th17 cells in disease pathogenicity. <i>Autoimmunity Reviews</i> , 2021 , 20, 102933	13.6	7
56	Composite endpoints for Sjögren's Syndrome [Authors' reply]. <i>Lancet Rheumatology, The</i> , 2021 ,	14.2	

55	Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research. <i>Nature Reviews Rheumatology</i> , 2021 , 17, 651-664	8.1	7
54	Salivary Gland Disorders and Diseases. 2018 , 1-85		1
53	Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	24
52	Recent advances in the search for a targeted immunomodulatory therapy for primary Sjögren's syndrome. <i>F1000Research</i> , 2019 , 8,	3.6	9
51	PROSPECTS FOR ANTI-B-CELL THERAPY IN IMMUNO-INFLAMMATORY RHEUMATIC DISEASES. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 57, 1-40	0.9	10
50	Primary Sjogren's syndrome in practice of gastroenterologist: difficult issues of diagnosis and treatment (clinical observation). <i>Medical Alphabet</i> , 2020 , 52-55	0.3	1
49	Efficacy of rituximab for glandular Sjögren's disease according to international clinical trials. <i>Sovremennaya Revmatologiya</i> , 2020 , 14, 85-92	0.7	
48	Targeted Therapy for Primary Sjögren's Syndrome: Where are We Now?. <i>BioDrugs</i> , 2021 , 35, 593-610	7.9	1
47	The effects of resistance training in patients with primary Sjogren's syndrome. <i>Clinical Rheumatology</i> , 2021 , 1	3.9	0
46	Peripheral Neuropathies Associated With Vasculitis and Autoimmune Connective Tissue Disease. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2020 , 26, 1257-1279	3	0
45	Mycophenolate for the Treatment of Primary Sjögren's Syndrome. <i>Journal of Translational Internal Medicine</i> , 2020 , 8, 146-149	3	1
44	Development and Application of the Placebo Response Model in Clinical Trials for Primary Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 2021 , 12, 783246	8.4	1
43	Primary Sjögren's syndrome: new beginning for evidence-based trials. <i>Lancet, The</i> , 2021 ,	4.0	0
42	Safety and efficacy of subcutaneous ivalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. <i>Lancet, The</i> , 2021 ,	4.0	7
41	Long-term abatacept treatment for 48 weeks in patients with primary Sjögren's syndrome: The open-label extension phase of the ASAP-III trial.. <i>Seminars in Arthritis and Rheumatism</i> , 2022 , 53, 151955	5.3	0
40	Why stratification is important in primary Sjögren's syndrome.. <i>Rheumatology International</i> , 2022 , 1	3.6	
39	Abatacept Ameliorates Both Glandular and Extraglandular Involvements in Patients With Sjögren's Syndrome Associated with Rheumatoid Arthritis: Findings from an Open-Label, Multicenter, 1-Year, Prospective Study: the ROSE (Rheumatoid Arthritis with Orencia Trial Toward Sjögren's Syndrome Endocrinopathy) and ROSE II trials.. <i>Modern Rheumatology</i> , 2022 ,	3.3	0
38	Off-Label Use of Biologics in Rheumatological Disorders. 2022 , 261-272		

37	Biologics in Sjogren's Syndrome. 2022 , 75-84		
36	Advancement in therapeutic strategies for immune-mediated oral diseases.. <i>Disease-a-Month</i> , 2022 , 101352		0
35	Development and preliminary validation of the Sjogren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjogren's syndrome.. <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	3
34	Safety and Efficacy of Filgotinib, Lanraplenib, and Tirabrutinib in Sjogren's Syndrome: Randomised, Phase 2, Double-Blind, Placebo-Controlled Study.. <i>Rheumatology</i> , 2022 ,	3.9	2
33	Labial Gland Mesenchymal Stem Cell Derived Exosomes-Mediated miRNA-125b Attenuates Experimental Sjogren's Syndrome by Targeting PRDM1 and Suppressing Plasma Cells.. <i>Frontiers in Immunology</i> , 2022 , 13, 871096	8.4	1
32	Cellular and molecular diversity in Sjogren's syndrome salivary glands: Towards a better definition of disease subsets. <i>Seminars in Immunology</i> , 2021 , 101547	10.7	1
31	Table_1.DOCX. 2019 ,		
30	Table_2.DOCX. 2019 ,		
29	Table_3.DOCX. 2019 ,		
28	Table_4.xlsx. 2019 ,		
27	Table_1.DOCX. 2020 ,		
26	Traitements futurs de la maladie de Sjogren. <i>Revue Du Rhumatisme Monographies</i> , 2022 ,		0
25	Prise en charge de la sécheresse buccale et oculaire. <i>Revue Du Rhumatisme Monographies</i> , 2022 ,		0
24	Current and future treatment in primary Sjogren's syndrome - a still challenging development.. <i>Joint Bone Spine</i> , 2022 , 105406	2.9	
23	Cardiovascular Involvement in Sjogren's Syndrome. <i>Frontiers in Immunology</i> , 2022 , 13,	8.4	0
22	Sjogren's and non-Sjogren's sicca share a similar symptom burden but with a distinct symptom-associated proteomic signature.. <i>RMD Open</i> , 2022 , 8,	5.9	0
21	Rituximab in chronic immune mediated neuropathies: a systematic review. <i>Neuromuscular Disorders</i> , 2022 ,	2.9	0
20	Predicting Sustained Clinical Response to Rituximab in Moderate to Severe Systemic Manifestations of Primary Sjogren Syndrome. <i>ACR Open Rheumatology</i> ,	3.5	0

19	Sjögren's Syndrome Dry Eye Disease. 2023 , 97-105		
18	Variability in primary Sjögren's syndrome is driven by interferon alpha, and genetically associated with the class II HLA DQ locus. <i>Arthritis and Rheumatology</i> ,	9.5	1
17	Sjögren's syndrome. <i>JDDG - Journal of the German Society of Dermatology</i> ,	1.2	
16	Traitements actuels et futurs du Syndrome de Sjögren primitif - un développement ambitieux. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2022 ,	0.1	
15	Sjögren-Syndrom. <i>JDDG - Journal of the German Society of Dermatology</i> , 2022 , 20, 980-1003	1.2	
14	Cytotoxic CD8+ T cells may be drivers of tissue destruction in Sjögren's syndrome. 2022 , 12,		0
13	Editorial: Advance in B-cell therapies for the treatment of rheumatic and musculoskeletal diseases. 9,		0
12	Engineering Cell Therapies for Autoimmune Diseases: From Preclinical to Clinical Proof of Concept. 2022 , 22,		0
11	Defining the Role of Monocytes in Sjögren's Syndrome. 2022 , 23, 12765		1
10	The Future of Targeted Treatment of Primary Sjögren's Syndrome: A Focus on Extra-Glandular Pathology. 2022 , 23, 14135		0
9	A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome. 2022 , 7,		0
8	Determinants of health-related quality of life across the spectrum of connective tissue diseases using latent profile analysis: results from the LEAP cohort.		0
7	Sjögren's syndrome: shedding light on emerging and key drug targets. 1-14		0
6	Brain mapping inflammatory-arthritis-related fatigue in the pursuit of novel therapeutics. 2023 , 5, e99-e109		0
5	Pathogenesis and treatment of Sjögren's syndrome: Review and update. 14,		0
4	World Workshop on Oral Medicine VIII: Development of a Core Outcome Set for Dry Mouth: A Systematic Review of Outcome Domains for Xerostomia.. 2023 ,		0
3	Genetics and epigenetics of primary Sjögren syndrome: implications for future therapies.		0
2	Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sjögren's syndrome: evidence- and practice-based guidance. 14,		0

- 1 Role of JAK-STAT signaling pathway in pathogenesis and treatment of primary Sjögren's syndrome. Publish Ahead of Print,

o